Hard chambers deliver 1,824 mmHg arterial oxygen at 2.4 ATA. Soft chambers deliver roughly 230 mmHg at 1.3 ATA. That is an 8x difference, and it shows in the research: zero published RCTs have demonstrated neurological or wound healing benefits from soft chambers. Every major positive HBOT trial used hard chambers at 1.5 ATA or above. This is not a preference. It is physics.
The Core Question
The soft vs hard chamber debate is the most consequential decision in HBOT. It determines whether you receive a therapy backed by randomized controlled trials or an intervention with limited published evidence at dramatically lower oxygen delivery.
The Physics: Henry’s Law
Oxygen dissolves into blood plasma according to Henry’s Law: the amount of dissolved gas is directly proportional to the partial pressure of that gas above the liquid. Here is what that means in practice for each chamber type:1
| Chamber Type | Pressure (ATA) | O2 Content | Arterial O2 (mmHg) | Relative Delivery |
|---|---|---|---|---|
| Normal breathing | 1.0 | 21% | ~157 | 1x (baseline) |
| Soft chamber (ambient air) | 1.3 | ~24% | ~230 | 1.5x |
| O2 mask at sea level | 1.0 | 55% | ~418 | 2.7x |
| Hard chamber (standard) | 2.0 | 100% | ~1,520 | 9.7x |
| Hard chamber (clinical) | 2.4 | 100% | ~1,824 | 11.6x |
“At 1.3 ATA with ambient air, a soft chamber produces arterial oxygen of ~230 mmHg. A hard chamber at 2.4 ATA with 100% O2 produces ~1,824 mmHg. That is an 8x difference in oxygen delivery.”1
The Bacteriostatic Threshold
One of the most clinically important distinctions between chamber types is the bacteriostatic threshold. Oxygen suppresses bacterial and fungal growth only at pressures above 1.5 ATA.2 Soft chambers at 1.3 ATA cannot achieve this. The South African Undersea and Hyperbaric Medicine Association states explicitly: “Mild hyperbaric exposures with air deliver no more oxygen to the body than breathing oxygen by mask at sea level pressure.”4
This is why soft chambers have no role in wound healing for infected tissue, gas gangrene, or necrotizing soft tissue infections — the conditions that most dramatically benefit from clinical HBOT.
What the Clinical Trials Used
Every major HBOT clinical trial demonstrating positive outcomes for neurological conditions used hard chambers:
- Long COVID (Zilberman-Itskovich et al., 2022): 2.0 ATA, 100% O2, hard chamber (full results)
- TBI (Harch et al., 2012): 1.5 ATA, 100% O2, hard chamber (full results)
- Stroke (Efrati et al., 2013): 2.0 ATA, 100% O2, hard chamber (full results)
- Fibromyalgia (Efrati et al., 2015): 2.0 ATA, 100% O2, hard chamber
- Anti-aging/telomeres (Efrati et al., 2020): 2.0 ATA, 100% O2, hard chamber
- Wound healing (Cochrane review): 2.0-2.4 ATA, 100% O2, hard chamber
“Not a single randomized controlled trial has compared soft-shell to hard-shell hyperbaric chambers for any medical condition.”5
For the detailed protocol comparison between major research programs, see our Efrati vs Harch protocol comparison.
Monoplace vs Multiplace Hard Chambers
Hard chambers come in two subtypes with important clinical differences. A 2023 study measuring tissue oxygenation in chronic ulcer patients found that levels at 1.4 ATA were approximately half those achieved at 2.0 ATA.6
| Feature | Monoplace | Multiplace |
|---|---|---|
| Capacity | 1 patient | 2-20+ patients + attendant |
| O2 delivery | 100% O2 fills chamber | Air-pressurized; O2 via mask |
| Max pressure | Typically 3.0 ATA | Up to 6.0 ATA |
| Critical care capability | Limited (no inside attendant) | Full ICU-level care possible |
| Purchase cost | $50,000-$150,000 | $500,000-$2,000,000+ |
What Soft Chambers Can Do
This is not an argument that soft chambers are worthless. They offer real value for specific use cases:
- Mild pressurization effects: The 1.3 ATA pressure itself provides some benefit through increased plasma oxygen and mild tissue compression
- Relaxation and recovery: Many users report improved sleep, reduced stress, and subjective well-being
- Athletic recovery: The modest oxygen increase may support recovery from intense training, though evidence is limited (athletic recovery data)
- Accessibility: At $4,495-$8,000, soft chambers make pressurized oxygen therapy accessible to consumers who cannot access clinical HBOT
FDA-cleared medical conditions: hard-shell chambers (14) vs soft-shell chambers (altitude sickness only)3
Price Comparison
| Option | Purchase Cost | Per-Session Cost (40 sessions amortized) |
|---|---|---|
| Soft chamber (home purchase) | $4,495-$12,000 | $112-$300 |
| Hard chamber clinic sessions | N/A (per-session) | $150-$400 per session |
| Hard chamber home purchase | $25,000-$42,999 | $625-$1,075 |
The Bottom Line
If you are pursuing HBOT for a specific condition with published clinical evidence (long COVID, TBI, stroke, wound healing, fibromyalgia, anti-aging), the evidence was generated in hard chambers at 1.5-2.4 ATA. Expecting soft chamber results to match is not supported by published data. A 2023 study measuring tissue oxygen in chronic ulcer patients found that levels at 1.4 ATA were approximately half those achieved at 2.0 ATA.6
If you want a wellness device for general health support, athletic recovery, and relaxation, a home-use soft chamber may be a reasonable investment — with the understanding that you are receiving a fundamentally different intervention than what clinical trials studied.
- Burman F. “Low-pressure fabric hyperbaric chambers.” South African Medical Journal. 2019;109(4). PMID: 31084683. doi:10.7196/SAMJ.2019.v109i4.13580
- HBOT USA. “Soft vs Hard HBOT Chambers: What Recent Research Reveals.” hbotusa.com. October 2025.
- UHMS Consumer Warning. “The Dangers of Soft-Sided Bag Chambers.” uhms.org
- Burman F. SAUHMA position statement on low-pressure fabric chambers. 2019. PMID: 31084683
- PMC. “A general overview on the hyperbaric oxygen therapy.” PMC8465921. 2021.
- Sack RA et al. “Transcutaneous oximetry values in chronic ulcer patients at 1.4 ATA vs 2 ATA.” Undersea and Hyperbaric Medicine. 2023. PMID: 38615347
- Lind F. “Pro/con review comparing mono- and multiplace hyperbaric chambers for critical care.” Diving and Hyperbaric Medicine. 2015. PMID: 25964041
- Efrati S, et al. “Hyperbaric oxygen induces late neuroplasticity in post stroke patients.” PLoS One. 2013;8(1):e53716.
- Zilberman-Itskovich S, et al. “Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition.” Scientific Reports. 2022;12:11252.
- Harch PG et al. “Systematic Review and Dosage Analysis: HBOT Efficacy in mTBI Persistent Postconcussion Syndrome.” Frontiers in Neurology. 2022. PMID: 35370898
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
